DK1447414T3 - Antagonistpeptider af carcinoembronisk antigen (CEA) - Google Patents

Antagonistpeptider af carcinoembronisk antigen (CEA)

Info

Publication number
DK1447414T3
DK1447414T3 DK04011673T DK04011673T DK1447414T3 DK 1447414 T3 DK1447414 T3 DK 1447414T3 DK 04011673 T DK04011673 T DK 04011673T DK 04011673 T DK04011673 T DK 04011673T DK 1447414 T3 DK1447414 T3 DK 1447414T3
Authority
DK
Denmark
Prior art keywords
cea
peptides
carcinoembryonic antigen
antigen antagonist
agonists
Prior art date
Application number
DK04011673T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1447414T3 publication Critical patent/DK1447414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04011673T 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA) DK1447414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
DK1447414T3 true DK1447414T3 (da) 2007-09-10

Family

ID=22036775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04011673T DK1447414T3 (da) 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA)

Country Status (11)

Country Link
EP (1) EP1017810B1 (el)
JP (1) JP4291508B2 (el)
AT (2) ATE364048T1 (el)
AU (1) AU745863B2 (el)
CA (1) CA2308127C (el)
CY (1) CY1107706T1 (el)
DE (2) DE69824023T2 (el)
DK (1) DK1447414T3 (el)
ES (2) ES2217585T3 (el)
PT (1) PT1447414E (el)
WO (1) WO1999019478A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010379A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
EP1964573B1 (en) 1999-10-22 2014-11-26 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
CN100337686C (zh) * 2002-12-04 2007-09-19 贝勒研究院 从前体产生加载有抗原的树突细胞疫苗的快速一步法
CN104147597A (zh) * 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
EP3539567A1 (en) 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
CN101765434B (zh) 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 抗肿瘤相关肽及相关抗癌疫苗组合物
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
CA2759013C (en) 2009-04-17 2021-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy compositions against cancer and methods
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE248924T1 (de) * 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
PT1447414E (pt) 2007-07-18
ES2217585T3 (es) 2004-11-01
WO1999019478A1 (en) 1999-04-22
DE69837896D1 (de) 2007-07-19
DE69837896T2 (de) 2008-02-14
CA2308127C (en) 2011-03-22
DE69824023T2 (de) 2005-05-12
AU745863B2 (en) 2002-04-11
EP1017810B1 (en) 2004-05-19
JP4291508B2 (ja) 2009-07-08
DE69824023D1 (de) 2004-06-24
EP1017810A1 (en) 2000-07-12
ATE364048T1 (de) 2007-06-15
ATE267213T1 (de) 2004-06-15
CA2308127A1 (en) 1999-04-22
AU9500498A (en) 1999-05-03
ES2286530T3 (es) 2007-12-01
JP2002500002A (ja) 2002-01-08
CY1107706T1 (el) 2013-04-18

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
PT935607E (pt) Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes
EA199800946A1 (ru) Концентрированный препарат антител
DE69942072D1 (de) Von der Telomerase abgeleitete antigene Peptide
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69533923D1 (de) Cytokinin-designiertes lerk-5
GEP20074091B (en) Cripto blocking antibodies and uses thereof
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
MY109957A (en) Improved antibodies to plasmodium falciparum
DE69934241D1 (de) Agonistische antikörper gegen tie2
GEP20105118B (en) Anti-vegf antibodies
CR8231A (es) Anticuerpos rg1 y uso de los mismos
DK1066380T3 (da) Opløselig T-cellereceptor
GB9204098D0 (en) Therapeutically useful peptides or peptide fragments
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
IL145689A0 (en) Methods
HU9300900D0 (en) Human gamma-interferon antagonists
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
EP1447414A3 (en) Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
DE69933875D1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
AU2002302751A1 (en) Dimerized t-cell receptor fragment, its compositions and use
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
EA199801032A1 (ru) Белки zona pellucida для контрацепции